Healthcare Sales & Marketing Network News: homozygous

Searching News Database: homozygous

HSMN NewsFeed - 25 Jan 2021
Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy(TM) (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies
Biopharmaceuticals Product Launch

HSMN NewsFeed - 25 Nov 2020
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy(TM) (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Aug 2020
FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 18 May 2020
Akcea Announces Appointment of New Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Oct 2019
Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Biopharmaceuticals Cardiology Reimbursement

HSMN NewsFeed - 14 Aug 2019
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol
Biopharmaceuticals Cardiology

HSMN NewsFeed - 23 Mar 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha(R) (evolocumab) Prevents Heart Attacks And Strokes
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 28 Jul 2017
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha(R) (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 20 Mar 2017
Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues
Biopharmaceuticals Cardiology

HSMN NewsFeed - 22 Feb 2017
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 3 Feb 2017
Amgen Announces Repatha(R) (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
Biopharmaceuticals Cardiology

HSMN NewsFeed - 9 Jan 2017
The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran (formerly, PCSK9si)
Biopharmaceuticals Cardiology

HSMN NewsFeed - 5 Dec 2016
Novelion Therapeutics Subsidiary, Aegerion Pharmaceuticals, Enters Into Licensing Agreement With Amryt Pharma for LOJUXTA(R) (lomitapide)
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 29 Nov 2016
Albireo Expands Team, Appoints Martha J. Carter as Chief Regulatory Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Aug 2016
New Repatha(R) (evolocumab) Analyses Show Efficacy and Safety Across Risk Groups in Results Presented at ESC Congress 2016
Biopharmaceuticals Cardiology

HSMN NewsFeed - 5 Jul 2016
Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 14 Apr 2016
Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 4 Feb 2016
Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha(R) (Evolocumab) In Statin-Intolerant Patients With High Cholesterol
Biopharmaceuticals

HSMN NewsFeed - 1 Feb 2016
Proteostasis Therapeutics Receives FDA Fast Track Designation for PTI-428 in Patients With Cystic Fibrosis
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Jan 2016
Amgen's Repatha(R) (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
Biopharmaceuticals Regulatory

HSMN NewsFeed - 22 Oct 2015
Merrimack Announces U.S. FDA Approval of ONIVYDE(TM) (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Sep 2015
Amgen To Acquire Privately-Held Dezima Pharma
Biopharmaceuticals Cardiology Mergers & Acquisitions

HSMN NewsFeed - 11 Sep 2015
Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha(TM) (Evolocumab)
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 6 Jan 2015
Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Jun 2014
Agena Bioscience Announces FDA 510(k) Premarket Clearance of the IMPACT Dx(TM) Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx(TM) System
Diagnostics FDA

HSMN NewsFeed - 20 Jan 2014
Aegerion Pharmaceuticals' JUXTAPID(R) (lomitapide) Capsules Approved in Mexico for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 25 Oct 2011
Aegerion Pharmaceuticals Appoints Craig E. Fraser as President, U.S.
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Jul 2011
Genzyme and Isis Announce Submission of European Marketing Authorization Application for Mipomersen (Kynamro(R))
Biopharmaceuticals Regulatory

HSMN NewsFeed - 21 Jul 2011
Aegerion Pharmaceuticals Announces Appointment of Paul G. Thomas to Its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Jun 2011
Kurt May to Join International Stem Cell Corporation as Senior Vice President
Regenerative Medicine Personnel

HSMN NewsFeed - 15 Feb 2011
Aegerion Pharmaceuticals Appoints Diane L. Tribble, Ph.D., M.M.Sc., as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Feb 2011
Aegerion Pharmaceuticals Appoints Martha J. Carter as Chief Regulatory Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Aug 2010
Impax Laboratories Confirms Patent Challenge Relating to VYTORIN(R), 10 mg/80 mg
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 22 Jun 2010
International Stem Cell Corporation Names Charles J. Casamento to Board of Directors
Regenerative Medicine Personnel

HSMN NewsFeed - 2 Mar 2010
International Stem Cell Corporation Parthenogenetic Stem Cell Line Shown to Carry the Most Common Immune Genes Matched to the U.S. Population Retains Stem Cell Characteristics over Two Years in Culture, Which is Necessary for Therapeutic Value
Regenerative Medicine

HSMN NewsFeed - 23 Nov 2009
ARCA Receives FDA Fast Track Designation for Gencaro(TM) Development in Genotype-Defined Heart Failure Population
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 20 May 2009
Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint
Biopharmaceuticals

HSMN NewsFeed - 24 Jun 2008
Genzyme and Isis Complete Licensing of Mipomersen
Biopharmaceuticals Licensing

HSMN NewsFeed - 25 Apr 2008
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Jan 2008
Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial
Biopharmaceuticals

HSMN NewsFeed - 14 Jan 2008
Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial
Biopharmaceuticals Cardiology

HSMN NewsFeed - 7 Jan 2008
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 20 Nov 2007
Merck/Schering-Plough Pharmaceuticals Provides Update on ENHANCE Trial
Biopharmaceuticals Cardiology

HSMN NewsFeed - 15 Oct 2007
Celera and Collaborators Identify a Five-Gene Genetic Risk Score(TM) That Predicts Risk of Coronary Heart Disease
Diagnostics Cardiology

HSMN NewsFeed - 8 Jun 2007
Schering-Plough and Bayer Healthcare Announce Availability of ZETIA in Japan, the First Cholesterol-Lowering Agent With a Novel Mechanism of Action Approved in Japan in 18 Years
Biopharmaceuticals Regulatory

HSMN NewsFeed - 17 May 2007
Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
Biopharmaceuticals

HSMN NewsFeed - 18 Apr 2007
Schering-Plough Announces ZETIA Approved in Japan for Treatment of High Cholesterol
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Mar 2007
Merck and Schering-Plough to Develop Another New Cholesterol Lowering Medicine
Biopharmaceuticals Cardiology

HSMN NewsFeed - 10 Jan 2007
New England Journal of Medicine Reports Aegerion's Lead Compound Reduces LDL By 51% in Patients With a Severe Form of Hypercholesterolemia
Biopharmaceuticals Cardiology

HSMN NewsFeed - 21 Dec 2006
Data Recently Published in Mayo Clinic Proceedings Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor (atorvastatin) in Reducing LDL ''Bad'' Cholesterol in Patients with Type II Diabetes at the Dose Comparisons Studied
Biopharmaceuticals

HSMN NewsFeed - 5 Oct 2006
FDA Approves New Label for VYTORIN(R) (ezetimibe/simvastatin)
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Jun 2006
Isis Pharmaceuticals Receives Orphan Drug Status for ISIS 301012 for the Treatment of Homozygous Familial Hypercholesterolemia
Biopharmaceuticals FDA

Return to NewsFeed

Additional items found! 16

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 16 additional stories matching:
homozygous
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.